Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion~* Cytologically or histologically confirmed adenocarcinoma of the breast~  * Stage I-III disease~ * BI-RADS 4 or 5 abnormalities on breast imaging and undergoing core needle biopsy for diagnosis~ * Participants must have a lesion of at least 1-cm on breast imaging studies (mammogram, ultrasound, or MRI)~ * Participants must have breast cancer amenable to surgery with curative intent and must have agreed to undergo such surgery~    * The surgical procedure must be scheduled in the near future to accommodate a treatment period of no less and no more than 15 days~* Clinically positive for the overexpression of EGFR and interleukin-1α~* Clinically negative for expression of the estrogen receptor (ER-negative) and progesterone receptor (PgR-negative)~  * May be positive or negative for HER2~Exclusion~* Locally advanced or metastatic disease not amenable to surgery~* Known brain metastases~PATIENT CHARACTERISTICS:~Inclusion~* Female~* Menopausal status not specified~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* ANC ≥ 1000/mm³~* Platelet count ≥ 75,000/mm³~* AST and ALT ≤ 2.5 times upper limits of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 2 times ULN~* Hemoglobin \> 9 g/dL~* Creatinine within normal institutional limits OR creatinine clearance \>60 mL/min~* Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and women within 6 months of menopause~* Women of child-bearing potential and their partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation~Exclusion~* Pregnant or nursing~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride~* Uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~Exclusion~* Received any other therapy (i.e., surgery, radiation, hormone treatment, biologic therapy, and/or chemotherapy) for the treatment of breast cancer~* Concurrent use of anti-neoplastic or anti-tumor agents not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy~* Receiving any other investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- erlotinib hydrochloride (Type: EXPERIMENTAL): Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).